The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

UK biotech Epsilogen has bought US-based TigaTx, pooling their resources to create what it says will be a leader in 'pan-isotope' cancer antibodies. Epsilogen rose to prominence a few years ago by ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

IgG antibodies are commonly used in cancer treatment. They help the body's immune system fight cancer and are being ...